Zealand Pharma announces closing of collaboration and license agreement with Roche

Core Insights - Zealand Pharma has successfully closed a collaboration and license agreement with Roche, which is now effective following the satisfaction of all closing conditions, including regulatory requirements [1] - The partnership is aimed at advancing Zealand Pharma's vision in obesity management, with a focus on the potential of petrelintide to benefit individuals who are overweight or obese [2] Company Overview - Zealand Pharma A/S is a biotechnology company specializing in the discovery and development of peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [3] - Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma also has a presence in the United States [4]